Completed PHASE3 INTERVENTIONAL 3-arm NCT00594958

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.

Sponsor: Valneva Austria GmbH

Conditions Japanese Encephalitis

Interventions IC51

Updated 7 times since 2017 Last updated: Mar 20, 2024 Started: Sep 30, 2006 Primary completion: Apr 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Japanese Encephalitis, this trial is completed. The trial is conducted by Valneva Austria GmbH and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Valneva Austria GmbH

Data source: Valneva Austria GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.